Ratan Capital Management LP Invests $646,000 in IQVIA Holdings Inc. $IQV

Ratan Capital Management LP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 3,342 shares of the medical research company’s stock, valued at approximately $646,000.

Other hedge funds also recently added to or reduced their stakes in the company. Apella Capital LLC raised its holdings in IQVIA by 5.1% during the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after buying an additional 60 shares in the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the last quarter. Breakwater Capital Group grew its position in shares of IQVIA by 3.2% in the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after buying an additional 64 shares during the last quarter. Finally, Keybank National Association OH raised its stake in IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock worth $2,052,000 after acquiring an additional 67 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Down 0.7%

Shares of IQVIA stock opened at $260.48 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. The company has a market capitalization of $42.88 billion, a P/E ratio of 32.32, a PEG ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $265.25. The company’s fifty day moving average is $222.14 and its two-hundred day moving average is $189.62.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the company earned $2.81 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. HSBC restated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. Robert W. Baird boosted their target price on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. raised their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada lifted their price target on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider directly owned 2,989 shares in the company, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.